[go: up one dir, main page]

WO1996006604B1 - Procedes d'identification et de traitement de tumeurs resistantes - Google Patents

Procedes d'identification et de traitement de tumeurs resistantes

Info

Publication number
WO1996006604B1
WO1996006604B1 PCT/US1995/011125 US9511125W WO9606604B1 WO 1996006604 B1 WO1996006604 B1 WO 1996006604B1 US 9511125 W US9511125 W US 9511125W WO 9606604 B1 WO9606604 B1 WO 9606604B1
Authority
WO
WIPO (PCT)
Prior art keywords
mrp
use according
pages
compound
protein
Prior art date
Application number
PCT/US1995/011125
Other languages
English (en)
Other versions
WO1996006604A2 (fr
WO1996006604A3 (fr
Filing date
Publication date
Priority claimed from US08/298,644 external-priority patent/US5543428A/en
Priority claimed from DE19944432563 external-priority patent/DE4432563C2/de
Application filed filed Critical
Priority to JP8508977A priority Critical patent/JPH10505348A/ja
Priority to EP95932371A priority patent/EP0777472A2/fr
Priority to AU35434/95A priority patent/AU3543495A/en
Priority to US08/793,659 priority patent/US6235785B1/en
Publication of WO1996006604A2 publication Critical patent/WO1996006604A2/fr
Publication of WO1996006604A3 publication Critical patent/WO1996006604A3/fr
Publication of WO1996006604B1 publication Critical patent/WO1996006604B1/fr
Priority to US09/836,429 priority patent/US6673813B2/en
Priority to US09/836,567 priority patent/US20020013370A1/en

Links

Abstract

L'invention concerne un procédé d'identification et d'inversion de la résistance multiple aux anticancéreux d'une tumeur, qui consiste à administrer une certaine quantité de n'importe lequel des composés définis dans cette invention, cette quantité étant suffisante pour réaliser l'inversion de la résistance multiple aux anticancéreux.
PCT/US1995/011125 1994-08-31 1995-08-31 Procedes d'identification et de traitement de tumeurs resistantes WO1996006604A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP8508977A JPH10505348A (ja) 1994-08-31 1995-08-31 耐性腫瘍の同定および治療方法
EP95932371A EP0777472A2 (fr) 1994-08-31 1995-08-31 Procedes d'identification et de traitement de tumeurs resistantes
AU35434/95A AU3543495A (en) 1994-08-31 1995-08-31 Methods for identifying and treating resistant tumors
US08/793,659 US6235785B1 (en) 1994-08-31 1995-08-31 Methods for identifying and treating resistant tumors
US09/836,429 US6673813B2 (en) 1994-08-31 2001-04-17 Methods for identifying and treating resistant tumors
US09/836,567 US20020013370A1 (en) 1994-08-31 2001-04-17 Methods for identifying and treating resistant tumors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/298,644 US5543428A (en) 1994-08-31 1994-08-31 Method for treating resistant tumors
US08/298,644 1994-08-31
DE19944432563 DE4432563C2 (de) 1994-09-13 1994-09-13 Verwendung von amphiphilen Anionen zur Verminderung der Zytostatika-Resistenz durch Hemmung des durch das MRP-Protein vermittelten Membrantransports
DEP4432563.0 1994-09-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/793,659 Continuation-In-Part US6235785B1 (en) 1994-08-31 1995-08-31 Methods for identifying and treating resistant tumors

Publications (3)

Publication Number Publication Date
WO1996006604A2 WO1996006604A2 (fr) 1996-03-07
WO1996006604A3 WO1996006604A3 (fr) 1996-08-01
WO1996006604B1 true WO1996006604B1 (fr) 1996-09-12

Family

ID=25940080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/011125 WO1996006604A2 (fr) 1994-08-31 1995-08-31 Procedes d'identification et de traitement de tumeurs resistantes

Country Status (6)

Country Link
US (3) US6235785B1 (fr)
EP (2) EP0777472A2 (fr)
JP (1) JPH10505348A (fr)
AU (1) AU3543495A (fr)
CA (1) CA2198752A1 (fr)
WO (1) WO1996006604A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006604A2 (fr) * 1994-08-31 1996-03-07 Eli Lilly And Company Procedes d'identification et de traitement de tumeurs resistantes
EP1115427B1 (fr) * 1998-09-25 2003-12-03 Horst Lindhofer Utilisation de cellules tumorales avec un decalage temporel en combinaison avec des anticorps intacts pour l'immunisation
AU1916501A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
AU2001261832A1 (en) * 2000-05-09 2001-11-20 Creighton University Methods for inhibiting proliferation and inducing apoptosis in cancer cells
JP2004513090A (ja) 2000-09-27 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
JP4350946B2 (ja) 2000-10-31 2009-10-28 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
JP2004522774A (ja) * 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体を用いる耐性腫瘍の治療
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
US10107437B2 (en) * 2015-09-15 2018-10-23 Mustang Sampling Llc Tooling friendly adapter for insertion probe access
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
WO2017095722A1 (fr) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1
WO2017095724A1 (fr) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Sulfonamides d'aryle utilisés en tant qu'antagonistes de blt1
US10450309B2 (en) 2015-11-30 2019-10-22 Merch Sharp & Dohme Corp. Aryl sulfonamides as BLT1 antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211791A (en) 1975-09-23 1980-07-08 Beecham Group Limited Indanediones
US4200577A (en) 1975-09-23 1980-04-29 Beecham Group Limited Coumarin derivatives
US4889871A (en) 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
US5216024A (en) 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5216172A (en) 1988-02-24 1993-06-01 Ajinomoto Co., Inc. 1,4-dihydropyridine-4-aryl-2,6-dimethyl-3,5-dicarboxylates useful as agents against drug resistant tumor cells
JPH02218654A (ja) * 1988-10-12 1990-08-31 Ono Pharmaceut Co Ltd 安息香酸誘導体、それらの製造方法およびそれらを含有する薬剤
ZA925185B (en) 1991-07-18 1993-04-29 Hoffmann La Roche Dithianes.
ES2116324T3 (es) 1991-11-25 1998-07-16 Lilly Co Eli Antagonistas de leucotrieno sustituidos con fenilfenol.
PH30449A (en) 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
EP0643693B1 (fr) 1992-02-06 1999-07-28 Merrell Pharmaceuticals Inc. Inversion de la resistance multi-medicament au moyen de derives de triphenyl-piperidine
CA2129143C (fr) 1992-02-06 1997-05-06 Sai Prasad Sunkara Renversement de la resistance a plus d'un medicament a l'aide de derives des tetraarylethylenes
AU5162293A (en) 1992-09-17 1994-04-12 Board Of Trustees Of The University Of Illinois, The Methods for preventing multidrug resistance in cancer cells
IL107462A0 (en) 1992-11-05 1994-02-27 Lilly Co Eli Drug resistance-conferring protein, antibodies reactive therewith and utilities thereof
US5324743A (en) 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
DK0652004T3 (da) * 1993-10-15 2002-09-02 Lilly Co Eli Fremgangsmåder til behandling af resistente neoplasmer
US5543428A (en) 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors
WO1996006604A2 (fr) * 1994-08-31 1996-03-07 Eli Lilly And Company Procedes d'identification et de traitement de tumeurs resistantes

Similar Documents

Publication Publication Date Title
WO1996006604B1 (fr) Procedes d'identification et de traitement de tumeurs resistantes
Kohn et al. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates
Watson Antidepressant drugs as adjuvant analgesics
Ross et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer
US5166207A (en) Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
KR960008234B1 (ko) 신경중독손상을 감소시키기 위한 약제 조성물
Jordan et al. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.
US20020128264A1 (en) Methods for treatment of conditions affected by activity of multidrug transporters
JP2000513009A (ja) カルシトニン擬似体
BRPI0212346B1 (pt) Compostos derivados de benzotiadiazepina ou um sal farmaceuticamente aceitável do mesmo com efeito inibidor de transporte de ácido de bile ileal, processo para a preparação dos mesmos, uso destes, e, composição farmacêutica.
US20090202572A1 (en) Compositions and methods for modulating bone mass
KR960037675A (ko) 벤조니트릴 및 벤조플루오라이드
MA27197A1 (fr) Sels de tolterodine
AU650265B2 (en) Novel derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present
CA2465886A1 (fr) Procedes servant a favoriser l'absorption et l'accumulation nucleaire de polyamides dans des cellules eucaryotes
Wardley FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA
AU731125B2 (en) Method for inducing death of neoplastic cells using piperazine oxirane derivatives
Alvarado et al. Effects of serotonin uptake blockers and of 5-hydroxytryptophan on the voluntary consumption of ethanol, water and solid food by UChA and UChB rats
Hwang et al. Interactions of sterols with antiestrogen-binding sites: structural requirements for high-affinity binding.
US20120058203A1 (en) Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2,3-d]pyrimidines
Nauta et al. Structure-activity relationships of H1-receptor antagonists
AU672234B2 (en) Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
Blanton et al. Examining the noncompetitive antagonist-binding site in the ion channel of the nicotinic acetylcholine receptor in the resting state
Macintosh et al. Hepatic fibrosis as a predictor of hepatic regenerative activity after partial hepatectomy in the rat
EP1633345B1 (fr) Compose inhibant la liaison de la proteine sap pour le traitement de l'arthrose